Ophthalmic drugs are used for the treatment of several eye diseases and disorders such as glaucoma, conjunctivitis, dry eye syndrome, infection, inflammation, and retinal disorders. Growing prevalence of various eye disorders, rise in ageing population and increasing healthcare expenditures are some key factors driving the demand for ophthalmic drugs.

The global Ophthalmic Drugs Market is estimated to be valued at US$ 48.19 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Growing prevalence of eye disorders is one of the key trends accelerating growth of the ophthalmic drugs market. According to the estimates of World Health Organization (WHO), about 2.2 billion people suffer from vision impairment or blindness globally. Cataracts, age-related macular degeneration, glaucoma, diabetic retinopathy are some of the major causes of vision impairment and blindness. 90% of people who are blind or have low vision live in low and middle income countries. Growing geriatric population who are more prone to develop eye disorders will further drive the market growth over the forecast period. Increasing healthcare expenditure per capita worldwide for the treatment of various eye diseases is also favoring the market growth.
 

Segment Analysis
The ophthalmic drugs market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment dominates the market currently due to higher efficacy and ability to treat severe eye disorders that require prescription. Within prescription drugs, anti-glaucoma drugs constitute the largest sub-segment as glaucoma is the leading cause of blindness globally. Glaucoma drugs like prostaglandin analogs, beta blockers etc. are prescribed to lower eye pressure and prevent further damage to the optic nerve.

Key Takeaways
The global Ophthalmic Drugs Market Demand is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: North America currently dominates ophthalmic drugs market owing to high healthcare expenditure and growing prevalence of eye disorders in the region. Asia Pacific is witnessing fastest growth and is expected to take over North America as the largest market due to rising geriatric population, growing cases of diabetes and increasing healthcare spending in countries like China and India.
Key players related content: Key players operating in the ophthalmic drugs market are Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc., Bausch & Lomb Incorporated, F. Hoffmann-LA Roche Ltd. (Genentech, Inc.), among others.

Explore more information on this topic, Please visit @ https://www.marketwebjournal.com/driven-by-increasing-prevalence-of-eye-diseases-share